NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SVRA

Savara Inc

Jul 07 • 04:00PM ET

2.34

Dollar change +0.15
Percentage change 6.85	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN RARE ARWR NVAX AXSM HRTX ACAD PTGX KPTI CRBP

| Held by: VTI IWM VXF IWO VTWO SCHA IBB LFSC ESML IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.49	Insider Own	54.78%	Shs Outstand	172.70M	Perf Week	5.88%
Market Cap	404.44M	Forward P/E	-	EPS next Y	-0.49	Insider Trans	0.22%	Shs Float	78.16M	Perf Month	-6.02%
Enterprise Value	261.58M	PEG	-	EPS next Q	-0.12	Inst Own	48.44%	Short Float	22.84%	Perf Quarter	-19.31%
Income	-102.17M	P/S	-	EPS this Y	-3.39%	Inst Trans	3.09%	Short Ratio	11.86	Perf Half Y	-23.78%
Sales	0.00M	P/B	2.73	EPS next Y	1.84%	ROA	-58.79%	Short Interest	17.85M	Perf YTD	-23.78%
Book/sh	0.86	P/C	2.34	EPS next 5Y	27.89%	ROE	-75.77%	52W High	5.11 -54.21%	Perf Year	-45.58%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	-14.63% 24.35%	ROIC	-57.60%	52W Low	1.89 23.81%	Perf 3Y	51.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.48% 7.68%	Perf 5Y	-13.33%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-31.15%	Oper. Margin	-	ATR (14)	0.18	Perf 10Y	-92.96%
Dividend Ex-Date	-	Quick Ratio	14.91	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.10	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	14.91	EPS Q/Q	-10.59%	SMA20	5.93%	Beta	0.39	Target Price	7.06
Payout	-	Debt/Eq	0.20	Sales Q/Q	-	SMA50	-10.50%	Rel Volume	1.78	Prev Close	2.19
Employees	59	LT Debt/Eq	0.20	Earnings	May 13 AMC	SMA200	-23.28%	Avg Volume	1.51M	Price	2.34
IPO	Oct 16, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.53% -	Trades		Volume	2,639,375	Change	6.85%

Date	Action	Analyst	Rating Change	Price Target Change
May-29-25	Downgrade	H.C. Wainwright	Buy → Neutral	$2
Dec-20-24	Initiated	Wells Fargo	Overweight	$8
Nov-13-24	Downgrade	Evercore ISI	Outperform → In-line	$7 → $5
Feb-15-24	Initiated	JMP Securities	Mkt Outperform	$8
Nov-07-23	Initiated	Guggenheim	Buy	$7
May-16-23	Upgrade	Jefferies	Hold → Buy	$2 → $4
Mar-31-23	Downgrade	Jefferies	Buy → Hold	$2
Mar-16-21	Initiated	Piper Sandler	Overweight	$7
Mar-15-21	Initiated	Oppenheimer	Outperform	$4
Jun-13-19	Reiterated	H.C. Wainwright	Buy	$22 → $6
Jun-13-19	Downgrade	Ladenburg Thalmann	Buy → Neutral	$21 → $3
Jun-13-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-13-18	Resumed	ROTH Capital	Neutral	$12
Jan-03-18	Initiated	Ladenburg Thalmann	Buy	$35
Sep-27-17	Resumed	ROTH Capital	Buy	$40
Sep-22-17	Initiated	Jefferies	Buy	$20
Sep-11-17	Initiated	JMP Securities	Mkt Outperform	$20

Show Previous Ratings

May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
02:30PM	Loading…
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
08:05AM	Loading…
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
08:05AM	Loading…
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Sep-24-24 08:05AM	Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately (Business Wire)
Sep-23-24 08:05AM	Savara to Host Analyst and Investor Webinar on September 30, 2024 (Business Wire)
Sep-08-24 06:45AM	Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 (Business Wire)
Sep-06-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-03-24 04:05PM	Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Sep-01-24 10:26PM	Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Aug-15-24 08:05AM	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 (Business Wire) +5.87%
Aug-12-24 04:05PM	Savara Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jun-29-24 08:35PM	Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-28-24 08:50AM	Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock (Business Wire) +5.77%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:30AM	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-25-24 08:05PM	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-19-24 09:00AM	3 Penny Stocks Poised for Major Upside Over the Next 5 Years (InvestorPlace)
Jun-11-24 06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
May-29-24 08:05AM	Savara to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-21-24 08:20AM	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating (MT Newswires)
May-19-24 12:15PM	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
May-16-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.08%
May-09-24 10:55PM	SVRA Stock Earnings: Savara Misses EPS for Q1 2024 (InvestorPlace) -8.19%
04:05PM	Savara Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-07-24 04:05PM	Savara to Present at the Citizens JMP Life Sciences Conference (Business Wire) +6.26% -5.13%
Apr-08-24 08:05AM	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 (Business Wire)
Mar-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-07-24 10:54PM	SVRA Stock Earnings: Savara Beats EPS for Q4 2023 (InvestorPlace) -5.19%
04:05PM	Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Mar-06-24 04:05PM	Savara to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire)
Feb-02-24 08:05AM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-31-24 08:05AM	Savara to Present at Two Upcoming Healthcare Conferences (Business Wire)
Dec-30-23 03:01PM	Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA) (GuruFocus.com)
Dec-21-23 08:05AM	Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Dec-20-23 08:05AM	Savara Added to the NASDAQ Biotechnology Index (Business Wire)
Dec-15-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Nov-21-23 08:05AM	Savara to Present at the Piper Sandler 35th Annual Healthcare Conference (Business Wire)
Nov-09-23 04:05PM	Savara Reports Third Quarter Financial Results and Provides Business Update (Business Wire) -7.84%
Nov-08-23 04:05PM	Savara to Present at the Jefferies London Healthcare Conference (Business Wire)
Oct-06-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Sep-27-23 07:29PM	3 Penny Stocks to Provide 1,000% Returns Over the Next Decade (InvestorPlace)
Sep-17-23 10:54AM	15 Penny Stocks with Biggest Upside (Insider Monkey)
Sep-12-23 09:12AM	The 3 Best Penny Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-05-23 04:05PM	Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-10-23 04:05PM	Savara Reports Second Quarter Financial Results and Provides Business Update (Business Wire)
Aug-04-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jul-13-23 07:00AM	Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire) +8.92%
Jun-26-23 04:05PM	Savara Added to Russell 3000® Index (Business Wire) -7.34%
08:05AM	Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Jun-02-23 08:05AM	Savara to Present at the Jefferies Healthcare Conference (Business Wire)
May-28-23 08:26AM	Independent Director of Savara David Ramsay Buys 4.8% More Shares \ (Simply Wall St.)
May-16-23 12:32PM	Why Shares of Savara Jumped on Tuesday (Motley Fool) +9.09%
May-15-23 08:05AM	Savara Reports First Quarter Financial Results and Provides Business Update (Business Wire)
May-05-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +6.84%
Apr-03-23 07:33AM	Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven In The Near Future (Simply Wall St.) -6.15%
Mar-31-23 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Mar-30-23 04:05PM	Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business Update (Business Wire)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -7.31%
Mar-16-23 06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research)
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research) -15.94%
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hawkins Richard J	Director	Jun 20 '25	Buy	2.04	48,225	98,572	115,466	Jun 23 02:39 PM
McCracken Joseph S	Director	May 29 '25	Buy	2.08	10,000	20,825	260,837	Jun 02 07:59 AM
RAMSAY DAVID A	Director	Mar 31 '25	Buy	2.77	150,000	416,250	2,513,642	Apr 01 07:00 AM
Lowrance David L	Chief Financial Officer	Dec 16 '24	Sale	3.33	25,000	83,278	381,005	Dec 16 05:59 PM
Pauls Matthew	CHIEF EXECUTIVE OFFICER	Dec 16 '24	Sale	3.31	54,702	180,828	1,536,379	Dec 16 05:56 PM
Hawkins Richard J	Director	Dec 16 '24	Sale	3.32	8,000	26,569	67,241	Dec 16 05:53 PM
Pauls Matthew	Director	Dec 16 '24	Proposed Sale	3.31	54,702	180,800		Dec 16 05:13 PM
Hawkins Richard J	Director	Dec 16 '24	Proposed Sale	3.29	8,000	26,300		Dec 16 03:15 PM
Lowrance David L	Officer	Dec 16 '24	Proposed Sale	3.30	25,000	82,500		Dec 16 03:08 PM
McCracken Joseph S	Director	Nov 19 '24	Buy	2.95	20,000	59,072	210,837	Nov 20 07:55 AM
RAMSAY DAVID A	Director	Nov 18 '24	Buy	2.88	100,000	287,600	2,323,642	Nov 18 12:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SVRA

Savara Inc

Upgrade your FINVIZ experience